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Abstract 
Interferons that trigger the release of innate antiviral proteins are a vital immune defense 
mechanism against viruses such as HIV-1. HERC5, an interferon stimulated protein inhibits 
HIV-1 replication through two independent mechanisms: inhibiting export of HIV-1 RNA 
through the Rev-dependent pathway and blocking an early step in the assembly of the virion. 
HERC5 is an antiviral protein yet individuals infected with HIV fail to control the infection. 
This can be due to viral antagonist mechanisms which counteract the function of restriction 
factors. Using a viral particle release assay, I discovered HIV-1 Env and Vpu can function as 
potential antagonists to HERC5. Furthermore, HIV-1 Env sequences derived from infected 
patients suggested that the antagonistic effect might be dependent on sequence dependent. 
Altogether, our data will be utilized to identify a novel target for the design of small 
molecule inhibitors to thwart the viral antagonism of HERC5. 
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Chapter 1  
1 Introduction 
In 1983, a research group led by Luc Montagnier discovered a retrovirus believed to be 
causing Acquired Immunodeficiency Syndrome (AIDS) (Barré-Sinoussi et al. 1983). The 
group isolated the virus form lymph nodes of patients presenting with general “flu-like” 
symptoms and named it lymphadenopathy-associated virus (LAV) until the virus was 
finally renamed to the Human Immunodeficiency Virus (HIV) in 1986.  
 HIV acute infection in patients presents as fever, malaise, and mouth and 
esophageal sores while the last stage is AIDS. Identified by a CD4+ T-cell count of less 
than 200 per microliter, a patient with AIDS becomes vulnerable to conditions such as 
cancer, pneumonia and opportunistic infections. Although no cure currently exists for 
HIV/AIDS, the treatment of infected individuals with antiretroviral therapy (ART) can 
drastically prolong their life. One of the challenges presented by HIV infection is the high 
genetic diversity that exists between viruses both within hosts and across populations 
(Alizon & Fraser 2013).  
Around the late 1970s, people started presenting with an unexplained severe 
immune deficiency. This was accompanied by a rise in opportunistic infections, such as a 
rare lung infection called Pneumocystis carinii pneumonia (PCP) and rare cancers, such 
as Kaposi’s sarcoma (Hymes et al, 1981; Masur et al. 1981). The symptoms also 
included a severe decline in cells containing a CD4 receptor. It was discovered that the 
root cause of this immunocompromised state was a virus known as Human 
Immunodeficiency virus (HIV) (Barré-Sinoussi et al. 1983; Barré-Sinoussi et al. 2013). 
HIV infects CD4+ cells by binding to the CD4 cell receptor to initiate its replication 
mechanism. As a result, infected CD4+ cells are recognized and killed by CD8+ 
cytotoxic lymphocytes. The decreased amount of CD4+ cells leads to a mitigated level of 
cellular immunity, causing the host to become immunocompromised and the body 
becomes more susceptible to opportunistic or common infections.  
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HIV exists in two main forms, HIV-1 and HIV-2. The vast genotypic differences 
(55% genetic difference) between these strains translates to different phenotypical 
capability such that HIV-1 is a far more ubiquitous and pernicious virus (Parry et al. 
2003; Dougan et al. 2005). HIV-1 can be broken down into subgroups with Group M 
causing the majority of infections worldwide (Figure 1). Although the other groups (N, 
O, P) contribute to cases of HIV-1 infection, group M is the most common. The four 
dominant HIV subtypes (M, N, O, P) are thought to be the consequence of 4 independent 
transmission events of SIV from chimpanzees to humans (Sharp & Hahn 2011). 
Meanwhile the genome derived from SIV of gorillas (SIVgor) and chimpanzees (SIVcpz) 
is mostly closely related to HIV-1 group O and P viruses (Van Heuverswyn et al. 2006). 
The group M viruses can be further classified by subtype as A, B, C, D, F, G, H, J and K 
(Figure 1). The circulating recombinant forms (CRFs) emerge from the amalgamation of 
two different subtypes, i.e. strain CM240 is a combination of subtypes A and E 
(Hemelaar, 2012). The dominant subtype in Western Europe and the Americas is subtype 
B while subtypes A, C and D are highly prevalent in Southern Africa and India (Fox et 
al. 2010). HIV was originally transferred to humans (a process known as zoonosis) in the 
early 20th century from chimpanzees (Gao et al. 1999). 
In the host, elevated mutation and recombination rates during viral replication 
generate viral diversity that is influenced by selection pressures by inherent host 
restriction factors and the immune response (Jia et al. 2015). In combination with the 
elevated mutation rate, HIV reverse transcriptase contributes to high genotypic diversity 
between viruses and can thus affect the viral phenotype. For example, genetic diversity in 
the genomic region of HIV-1 can give rise to a group of related viruses, called a viral 
quasispecies and alter the phenotype of the virus. In fact, particular viral subtypes differ 
by sequences and infected individuals with varying subtype viruses have symptoms 
varying in magnitude and slower disease progression (Venner et al. 2016). Therefore, the 
infectivity of HIV-1 is correlated to the subtype of the virus which is defined by the viral 
sequence.  
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Figure 1.  Breakdown of HIV strains, subtypes and groups. CRFs are circulating 
recombinant forms. The majority of HIV strains are HIV-1, which is subdivided into 
groups (M, N, O, P). 
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  Viral replication  
1.1.1 Overview 
HIV-1 is part of the Retroviridae family, a group of viruses that use reverse transcriptase 
to produce DNA from their natural RNA genome. The HIV genome consists of various 
viral genes (Gag, Pol, Env, Tat, Nef, Vif, Vpu, and Vpr) (Figure 2). In addition, two 
distinct sequences called LTRs (long terminal repeats) flank the 5’ and 3’ end of the 
HIV-1 genome (Li et al. 2015). 
To facilitate viral entry, the envelope protein (Env) in HIV-1 binds to the CD4 
receptor of a host cell and subsequently binds to the corresponding co-receptor(s), (CCR5 
and CXCR4), thereby triggering the fusion of the virion to the host cell (Deng et al. 1996; 
Wilen et al. 2012). The viral RNA is inserted and reverse transcribed in the host cell 
cytoplasm to create complimentary DNA (cDNA). The viral cDNA is integrated into the 
host genome where it is transcribed into mRNA. Following transcription, HIV-1 mRNA 
is exported from the nucleus to the cytoplasm where it is translated into viral proteins. 
Following the synthesis of the viral proteins, the mature virion is assembled and buds out 
of the host cell membrane (Fischer et al. 1995). 
 
1.1.2 HIV-1 Envelope and Entry 
The production of HIV-1 envelope is initiated in the host cell nucleus. The integrated 
DNA is transcribed into viral RNA and following transcription, the Env mRNA is 
exported to the endoplasmic reticulum where it is translated by the ribosomes to create a 
~850 amino acid precursor protein (Wyatt & Sodroski 1998). This precursor is modified 
by adding asparagine linked, high mannose content sugar chains, thus creating the 
intermediate, unstable gp160. Gp160 glycoprotein forms homotrimers before being 
exported to the Golgi apparatus, where it is cleaved by the host cellular protease into 
gp120 (surface protein) and gp41 (transmembrane protein) homotrimers (Wyatt & 
Sodroski 1998). These individual trimers are modified by glycosylation and non-  
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Figure 2.  HIV-1 virion and viral genes 
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covalently linked to form the gp120-gp41 heterodimer complex (Figure 3). This mature 
form of the Env protein is embedded on the surface of budding virions (Freed 2001). 
Gp120 consists of five conserved regions (C1-C5) and five highly variable 
domains (V1-V5), while gp41 is organized into three major domains: the ectodomain, the 
transmembrane domain and the cytoplasmic tail. Mutations in the gp41 cytoplasmic tail 
hinder the incorporation of Env into the mature virion (Murakami & Freed 2000). The V3 
loop in gp120 is vital in recognizing the coreceptor the virus binds to (Freed 2001). The 
attachment to both a CD4 receptor and a corresponding co-receptor triggers Env-
mediated membrane fusion of the virion to the host cell (Wilen et al. 2012).  
The binding of gp120 to the CD4 receptor exposes the flexible V1/V2 and V3 
loops. The exposed loops interact with the N-terminus of the extracellular loop of the 
coreceptor, thereby initiating the conformational change required for gp41 to facilitate 
membrane fusion (Freed 2001). The ectodomain of gp41 contains a highly hydrophobic 
N-terminus, termed “fusion peptide” which is necessary for membrane fusion. The 
transmembrane segment of gp41 brings the virus and host cell surface together to induce 
the formation of a fusion pore. The fusion pore allows for the insertion of the viral core 
into the cell, which contains genetic code of the virus into the cytoplasm of the cell (Chan 
et al. 1997). 
The HIV-1 Env protein facilitates the fusion and entry of the virus into the host 
cell. The surface (SU) protein, gp120 is responsible for the anchoring, interaction and 
binding to the cellular receptors and co-receptors. Viral entry is initiated when gp120 
subunit binds to a cell CD4 receptor (Lapham et al. 1996). However, to penetrate the host 
cell, the binding to the corresponding co-receptor, CCR5 (R5 tropism) or CXCR4 (X4 
tropism), is required (Dragic 2001). The binding of the co-receptor is also facilitated by 
the gp120 subunit. The co-receptor (or viral tropism) determines the type of cell HIV-1 
infects (Figure 4). The transmembrane (TM) protein, gp41 anchors the virion to the host 
cell membrane and catalyzes the membrane fusion between the viral and host cells to 
allow delivery of the capsid core to the cytoplasm. (Wyatt & Sodroski 1998). 
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Figure 3. Schematic of the HIV-1 Env protein. A) gp160 precursor is modified by 
adding asparagine linked, high mannose content sugar and exported to Golgi apparatus 
and cleaved by proteases to create gp120 and gp41 homotrimers. Individual trimers are 
modified by glycosylation and non-covalently linked to form the gp120-gp41 
heterodimer complex. B) Env gp120 is divided into constant [C] and variable [V] 
domains. The gp41 contains the ecto, transmembrane and cytoplasmic domains. 
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CD4 receptors and CCR5/CXCR4 co-receptors have an innate physiological 
function, where CD4 is involved in monitoring cytokine production and T-cell activation 
while the co-receptors function as chemokine receptors (Koretzky, 2010). CD4+ T-cells 
are also referred to as mature T-helper cells and are responsible for releasing cytokines 
that activate cytotoxic T cells. HIV-1 is able to exploit these chemokine receptors in 
order to enter the host cell. A small sequence in the gp120 region (called the V3 loop) of 
Env determines the type of co-receptor the virus binds to. But genotypic variations 
contribute to the phenotype of HIV-1. Interestingly, R5 HIV-1, also known as M-tropic 
due to their ability to infect macrophages, are responsible for the vast majority of HIV-1 
infections (Figure 4). Furthermore, R5 viruses replicate more efficiently in CD4+ T-cells 
than X4 viruses (Schweighardt et al. 2004). Whereas patients with X4 virus infection 
generally have lower average CD4+ T-cell counts, steeper CD4+ T-cell decline over 
time, and higher viral loads than patients with exclusively R5-tropic virus (Waters et al. 
2008).  
The CCR5 receptor is predominantly used by transmitting viruses (viruses spread 
from one individual to another) but the CXCR4 virus is found to evolve during disease 
progression in patients (Clapham & McKnight, 2001), due to the exhaustion of CCR5+ 
cells. The CCR5 gene has been shown to be vital in the transmission of HIV-1 and 
disease progression. A rare polymorphism in the CCR5 gene is the 32-base pair deletion 
in the exonic region (CCR5 Δ32), creating a defective CCR5 product that is unable to 
bind to the cell surface (Benkirane et al. 1997), thereby preventing host cell infection. 
1.1.3 Reverse transcription  
A crucial step in the replication cycle of retroviruses is the ability to reverse transcribe 
complimentary DNA (cDNA) from genomic RNA using the reverse transcriptase enzyme 
(Telesnitsky & Goff 1997). Reverse transcriptase (RT) is a heterodimer compromised of 
a 66 kDa (p66) and a 51 kDa subunit produced from the cleavage of a polyprotein by 
HIV-1 viral protease (PR). The 51 kDa subunit is created after a cleavage event by the 66 
kDa HIV-1 protease enzyme. Although the two subunits show a significant amount of  
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Figure 4. HIV-1 tropism determines infected cell type. CD4 is expressed on the 
surface of T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. 
CCR5 is predominantly expressed on T cells (memory and activated CD4 lymphocytes), 
gut associated lymphoid tissues (GALT), macrophages, dendritic cells, and microglia. 
CXCR4 is expressed on T cells (naïve and resting CD4 lymphocytes, as well as CD8 
cells), B cells, neutrophils, and eosinophils. Depending on the viral tropism, HIV-1 
targets cells with different receptors.  
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sequence overlap, the structural conformation is quite different and the polymerase active 
site is contained on the p66 subunit (Telesnitsky & Goff 1997).  
To initiate transcription, a primer and a template is required. The template is 
provided by the genomic RNA of HIV-1 and the primer is a tRNA molecule whose 3′ end 
is base paired to a complementary sequence near the 5′ end of the viral RNA called the 
primer binding site (pbs). The DNA synthesis is conducted from the 3’ to the 5’ end of 
the template RNA molecule, forming a DNA-RNA hybrid structure. The RNaseH 
enzyme, (part of the uncleaved RT enzyme), degrades the RNA portion of this complex 
and forms a minus-strand DNA sequence. However, in the RNA genome, purine-rich 
sequence known as the polypurine tract (ppt) is impervious to the enzymatic activity of 
RNaseH and acts as a primer for the initiation of the plus-strand DNA (Charneau et al. 
1994). The tRNA molecule bound to the pbs that is serving as a primer is also removed 
by RNaseH thereby allowing the plus stranded DNA synthesis to commence. The second 
strand (+ strand) cDNA sequence is created in a 5’ to 3’ direction from the viral RNA 
(Lanchy at al. 2000). 
During the last step of reverse transcription, the generation of the + stranded DNA 
leads to approximately 100 nucleotides being displaced in the strand, creating a “DNA 
flap” in the complex which has been implicated in the nuclear import of pre-integration 
complex (PIC) (Zennou et al. 2000), alongside the protein, Viral protein R (Vpr) (Popov 
et al. 1998). 
Interestingly, HIV-1, among other retroviruses, include two copies of single 
stranded RNA genome in each virion. Given the ability of the reverse transcriptase 
enzyme to translocate from the minus strand to the plus strand, the RT and template 
interaction is of a relatively low affinity (Temin, 1993). If the initial template RNA 
molecules are not genetically indistinguishable, this template switching causes the 
formation of novel recombinant genomes that are incorporated into the mature virions. 
Coupled with the high mutation rate of HIV-1 Reverse Transcriptase (3 X 10-5 errors per 
cycle of replication) (Mansky & Temin, 1995), virus populations – even within patients – 
have a high diversity, contributing to host immune evasion and antiviral drug resistance.  
11 
 
1.1.4 Integration  
Following transcription, the newly synthesized viral cDNA and the PIC aids the viral 
genome in being imported through the host nucleus. The PIC includes the HIV-1 cDNA, 
integrase (IN), RT, matrix antigen (MA), and viral protein R (Vpr). The nuclear 
localization signals contained in the MA and Vpr are hypothesized to direct the import of 
the viral cDNA (Popov et al. 1998).  
The insertion of the imported double stranded viral cDNA into the host cell 
genome is catalyzed by a 32 kDa protein, IN. The process is initiated upon the trimming 
of two nucleotides from the 3’ termini of both strands of the viral DNA, called 3'-end 
processing. This step is proceeded by strand transfer, a step where IN creates a staggered 
cleavage in the host cell DNA strand, allowing the processed 3’ends of the viral DNA to 
bind and integrate into the host chromosome (Farnet & Bushman 1996). The integrated 
genome, referred to as a provirus, allows the virus to lay dormant in host cells to escape 
immune responses and allows the infection to persist (Siliciano & Greene, 2011). 
1.1.5 Transcription  
After integration, replication is conducted by the host cell replication machinery. 
Replication is initiated by viral transcription at the long terminal repeats (LTR) region, 
made up of 3 major elements: Unique, 3' end (U3), Repeated (R) and Unique, 5' end (U5) 
(Freed, 2001). U3 encompasses a site that allows RNA polymerase II to bind in order to 
initiate transcription. An important transcription element called the TATA box is located 
approximately 25 nucleotides upstream of the transcription initiation site. Upstream of 
the TATA box are binding sites for Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), a protein vital for transcription to occur. Studies indicate that 
the absence of NF-κB abolishes HIV-1 transcription in certain cell types (Ross et al. 
1991).  
 A critical factor for HIV-1 transcription is a 101-amino acid protein, Trans-
activator of transcription (Tat). Tat functions by interacting with an RNA stem-loop 
structure found on the 5’ end on HIV-1 mRNA, called the trans-activating response 
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element (TAR), thereby recruiting transcription elongation complexes and enhancing 
traction. (Das et al. 2011). The presence of Tat is paramount as the basal level of viral 
transcription is minute when Tat is absent. In fact, the production of Tat protein increases 
transcription by a magnitude of two logs (100x) (Dayton et al. 1986) 
1.1.6 RNA Export 
After transcription, the HIV-1 transcripts are exported from the nucleus to the host cell 
cytoplasm. Viral mRNAs produced from transcription fall into one of three categories: 
unspliced mRNAs, partially spliced mRNAs, and multiply-spliced mRNAs. Each subset 
of mRNAs code for different proteins, i.e. the unspliced mRNAs serve as transcripts for 
Group specific antigen (Gag) and the GagPol polyprotein complex while the partially 
spliced mRNAs code for Env, Viral infectivity factor (Vif), Viral protein unique to HIV-
1 (Vpu), and Vpr (Rose et al. 2004). The fully spliced RNAs code for the regulator of 
expression of viral proteins (Rev), Tat, and Nef (Negative factor). The partially and 
unspliced mRNAs are transported through the Rev/CRM1 pathway while the fully 
spliced mRNAs are transported through the NXF1/Tap pathway (Taniguchi et al. 2014).  
Rev is a particularly important molecule as it acts as a shuttle for incompletely 
spliced mRNAs from the nucleus to the cytoplasm. This 116-amino acid phosphoprotein 
consists of two functional domains: an RNA binding/nuclear localization domain and a 
domain facilitating nuclear export.  The Rev protein exports mRNAs by binding to the 
cis-acting RNA element, Rev response element (RRE) (Pollard & Malim 1998). RRE is a 
250 nucleotide, RNA stem loop structure existing in all unspliced and partially spliced 
viral RNAs. RRE is located in the reading frame of the Env gene in the HIV-1 genome. 
Export of incompletely spliced RNA is initiated with the recruitment of a Rev molecule 
onto the stem loop structure (RRE). This is followed by recruitment of other Rev proteins 
which through protein-protein interactions create a Rev multimer, where approximately 8 
Rev proteins bind per RRE stem loop structure (Freed 2001).  
The complex of Rev/RRE is able to interact with cellular nuclear export 
machinery, such as the Chromosomal Region Maintenance 1 (CRM1) protein and 
transport unspliced or partially spliced RNAs to the cytoplasm (Fischer et al. 1995). The 
13 
 
CRM1 binds to the Ras-related-nuclear protein (Ran)-GTP, which then associates with 
the Rev/viral RNA complex. The Rev/viral RNA/RanGTP/CRM1 complex is transported 
from the nucleus to the cytoplasm due to an interaction with nuclear pore proteins. Once 
in the cytoplasm, the cytoplasmic Ran GTPase Activating Protein (RanGAP) and Ran 
binding protein 1 (RanBP1) bind RanGTP from the complex and converts it to RanGDP, 
thereby causing the dissociation of Rev/viral RNA/RanGTP/CRM1 complex. The Rev 
and RanGDP molecules are transported back into the nucleus where a guanine nucleotide 
exchange factor (GEF) for Ran called nuclear regulator of chromosome condensation 1 
(RCC1), changes the RanGDP to RanGTP, to restart another round of export (Figure 5) 
(Blissenbach et al. 2010; Suhasini et al. 2009; Askjaer et al. 1998; Melchior, 2001). 
Some retroviruses use a Rev-independent mechanism for export of this 
incompletely spliced RNA, i.e. the Mason-Pfizer monkey viruses (MPMV).  These 
viruses contain a Constitutive transport element (CTE), replacing the RRE with CTE in 
HIV-1 RNAs abolishes the necessity for Rev (Suptawiwat et al. 2005). The majority of 
eukaryotic RNAs, including CTE-containing RNAs, are spliced in the nucleus to remove 
intronic regions before being exported to the cytoplasm via the NXF1 (or TAP) (Grüter et 
al. 1998).  
1.1.7 Viral assembly and budding 
The viral mRNA is translated at the host cell ribosomes following export. The production 
of the viral proteins is followed by assembly. An important part of the replication process 
is the Gag precursor polyprotein, Pr55, which codes for core and structural proteins of the 
virus. Its roles include encapsulating the viral RNA genome, incorporation of the Env 
glycoproteins, packaging the GagPol Pr160 complex into mature virions and instigating 
the budding of the virion from the cell (Bell & Lever, 2013). Gag consists of a Matrix 
protein (MA), a capsid protein (CA), a nucleocapsid protein (NC), and a p6 protein 
(Waheed & Freed 2012). The assembly of the viral progeny is initiated through the 
formation of “Gag-Gag” interactions.   
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Figure 5. The export of Rev dependent unspliced HIV-1 mRNA using the CRM1 
cellular protein. HIV-1 mRNA is exported through a nuclear pore complex after the 
association with the RRE stem loop with Rev, which associates with the CRM1 and 
RanGTP proteins. A proper RanGTP to RanGDP ratio is required for the export of 
nuclear mRNAs. After export, the produced Ran GDP, Rev and CRM1 are recycled back 
to the nucleus to begin the export process 
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Following assembly, virus particles need to bud from the host cell membrane and 
this is accomplished through a process known as budding, where the virion “pinches off” 
the cell membrane. This event is mediated by sequences known as “late” or “L” domains 
responsible for promoting particle release. For HIV-1, the L domain is encoded in p6 of 
the Gag protein (Demirov et al. 2002). Budding is the penultimate step before viral 
maturation, and it involves the viral protease cleaving Gag and GagPol precursors to form 
the mature Gag and Pol protein, leading to the formation of a mature, pernicious HIV-1 
virions.  
 
  Host-pathogen interactions 
The presence of a foreign pathogen or biological agent is met with an immune response 
from the host. There are essentially two main types of immune responses: adaptive and 
innate. Adaptive immunity encompasses more long-term response to viral infections, 
such as creating an “immunological memory”. Innate immunity is a more immediate 
defensive system, as it is responsible for the creation of immune signalling molecules 
such as cytokines and chemokines, which recruit immune cells to the site of the infection, 
and activate the adaptive immune system. Among the cells recruited to sites of infection 
are dendritic cells, which are responsible for the release of Type I interferons (IFNs), a 
group of signaling proteins designed to protect cells from viral infections (Le Bon & 
Tough 2002). 
 In a typical infection event, a virus goes through a multi-stage replication process 
and eventually buds from the cell membrane. Conversely, the innate immune response to 
a foreign invader is the production and secretion of IFNs, triggering the synthesis of host-
encoded restriction factors (Malim and Bieniasz 2012). Restriction factors are defined as 
host proteins that can counteract or resist viral replication. These antiviral proteins such 
as Tethrin, APOBEC3G (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3G), SAMHD1 (SAM domain and HD domain-containing protein 1), HERC5 
(HECT domain and RCC1-like domain containing protein 5), and TRIM5ɑ (Tripartite 
motif-containing protein 5) provide a countermeasure to viral infection by the immune 
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system (Kluge et al. 2015). HIV-1 restriction factors function multiple ways to inhibit 
viral replication. Proteins such as TRIM5alpha cause a premature capsid disassembly and 
disruption of reverse transcription of the viral RNA while KAP1 (KRAB-associated 
protein 1)/ TRIM28 hinders viral replication by inducing deacetylation of the HIV 
integrase enzyme (a system positively regulated by acetylation) (Kluge et al. 2015).  
The concept of genetic conservation and diversity can be extended to 
host/pathogen symbiotic relationships in an evolutionary model called the Red Queen 
hypothesis. It has long served as a theoretical framework for deciphering host-pathogen 
relationships (Van Valen, 1973). The general idea is when two organisms are competing 
for survival, they will chronically co-evolve and compete in order to survive. But this 
adaptation creates an evolutionary standstill where both organisms continue to gain an 
advantage over their rival thus creating a dynamic co-evolution. When a sequence or a 
genetic element is conserved, it is said to be positively selected, as it confers a direct 
fitness advantage to the organism. However, change over time can be in favor of the host 
or the pathogen as both the host and the pathogen attempt to get the upper hand in this 
evolutionary arms race. It can lead to maintaining resistance to a pathogen (antiviral 
activity), or susceptibility within a host (HIV-1 overcoming cellular antiviral defenses), 
providing the pathogen with a survival advantage.  
1.2.1 Viral antagonism  
In order to maintain this survival advantage, viruses such as HIV-1 have evolved 
mechanisms to counteract host immune responses, especially the mechanisms of 
restriction factors. As the body’s first response to infection is activation of the IFN 
response, the virus must counteract the restriction factors which are highly upregulated 
during IFN release. The Nef protein, often referred to as the “Swiss army knife” protein 
has been shown to enhance the infectivity and survival of HIV through multiple 
functions. One function involved inactivation of host restriction factors such as Serine 
incorporator 3 (SERINC3) and Serine incorporator 5 (SERINC5). These factors reduce 
the efficiency of virus fusion with target cells through their incorporation into the virion 
during budding. To counteract this effect, Nef is able to redirect SERINC5 away from the 
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mature virion and exclude it from being packaged into HIV-1 particles (Rosa et al. 2015). 
A recent study by Beitari et al., 2017, showed that the Env protein of some HIV-1 strains 
is also able to overcome SERINC5 inhibition.  
BST2/Tetherin, a protein capable of tethering mature virions to the surface of 
infected cells to restrict HIV infection was found to be antagonized by the Vpu protein in 
HIV-1 (Neil et al. 2003) and Env in HIV-2. The antagonism of BST2/Tetherin by HIV-2 
Env or HIV-1 Vpu is also an event that occurs at the host cell’s plasma membrane 
(Hauser et al. 2010). HIV-1 Vpu antagonizes BST2/Tetherin by deterring the recycling of 
internalized BST2/Tetherin to the cell surface, inhibiting anterograde transport of the 
restriction factor and relocating BST2/Tetherin from the site of viral assembly at the host 
cell membrane (Pujol et al. 2016). 
  
APOBEC3G, an editing enzyme and restriction factor is thought to arise from 
gene duplication events (LaRue et al. 2009). The APOBEC3 family (APOBEC3F and 
APOBEC3G) of genes particularly, are cytidine deaminases unique to mammals and 
require the cytidine deaminase activity to inhibit HIV-1 replication (Miyagi et al. 2007). 
The deamination event leads to a strong degree of hypermutation in the viral negative 
sense single-stranded DNA, thereby inhibiting HIV-1 replication (Goila-Gaur and Strebel 
2008). APOBEC3 was found to be vulnerable to degradation by a ubiquitination 
dependent pathway that is stimulated by the HIV-1 Vif protein (Yu et al. 2003; Mehle et 
al. 2003). The function of Vif remains largely unclear. Although it has been found to 
interact with Gag, viral protease and capsid protein, the precise mechanism of Vif and 
viral replication continues to be ambiguous. (Lake et al. 2003; Franzdóttir et al. 2016).  
 
  HERC5 
One of the most potent restriction factors is HERC5. HERC5 is a ubiquitously expressed 
117kDa protein expressed in primary cells and upregulated by IFN, interleukin-1 and 
tumor necrosis factor-alpha. HERC5 levels are highly expressed in both the testes and 
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ovaries. The HERC5 gene is one of six human HERC family genes located on 
chromosome 4 and flanked by HERC6 and HERC3. The HERC5 protein is 1024 amino 
acids in length and comprises 2 domains, and a Spacer region which joins the two 
domains (Figure 6).  
HERC5 contains a Homologous to the E6 carboxyl terminal (HECT) domain, 
which is responsible for the covalent linkage of the Interferon-stimulated gene 15 
(ISG15) protein to substrate proteins in a ubiquitin-like conjugation action (Wong et al. 
2006). In terms of the ISGylation process, the HECT domain functions as an E3 ligase, 
meaning it plays an integral part in the covalent linkage of the ISG15 to the substrate. 
The Regulator of chromosome condensation 1(RCC1) -like domain (RLD) encompasses 
the amino terminus of HERC5 while the HECT domain is located at the carboxyl 
terminus. HERC5 is an IFN-induced protein that blocks the replication cycle of the HIV 
virus (Woods et al. 2014; Woods et al. 2011; Paparisto et al. 2018). It should be noted 
that the function of the spacer is unknown but the RLD plays a substantial role in 
HERC5-mediated inhibition of nuclear export (Woods et al. 2014). The RLD shares 
approximately 35% sequence indentity with RCC1 however predictive modelling of the 
HERC5 RLD shows a strong structural similarity with RCC1 (Figure 6). 
The RCC1 protein is a guanine exchange factor (GEF) capable of generating the 
appropriate RanGTP/RanGDP gradient between the nucleus and cytoplasm to allow for 
mRNA transport (Melchoir 2001). The RanGTP/RanGDP gradient is utilized by the HIV-
1 Rev protein to export unspliced HIV-1 RNA from the nucleus to the cytoplasm. The 
disruption of this gradient by HERC5 blocks export of the HIV-1 RNA from the nucleus 
and hinders replication. This mechanism is not fully understood; however, previous data 
in our lab showed HERC5 decreases the intracellular levels of RanGTP and/or inhibits 
the association of RanGTP with RanBP1, thereby halting the function of Rev-dependent 
export (Woods et al. 2014).  
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Figure 6. HERC5 contains a HECT and a RLD domain. A) Schemitic of the HERC5 
domains. B) Comparing the RCC1 and HERC5 RLD domains. Both domains encompass 
7 bladed propellers, where each propeller is made up of 4 β-sheets. The structure of the 
two domains is similar despite variation between the two sequences. Photo courtesy of 
Dr. Stephen Barr.  
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ISG15 is a ubiquitin-like protein that is conjugated to target proteins by HERC5. 
The tagging process is comprised of the E1 protein, the activating enzyme to which 
ISG15 is initially attached. This step is followed by a ubiquitin-conjugating enzyme, 
which facilitates that transfer of ISG15 to E2. E2 is called ubiquitin-conjugating enzyme 
and it covalently attaches ISG15 to the appropriate substrate to with the assistance of a 
ligating protein (E3 ligase) (Wong et al. 2006).   
HIV-1 Gag is one of the ISGylation targets of HERC5. Gag is a structural protein, 
which plays a role in viral assembly and post-assembly particle release. The attachment 
of an ISG15 group to the Gag protein causes the arrest of the assembly of HIV-1 Gag 
particles at the host cell membrane, thereby inhibiting HIV-1 replication. (Woods et al. 
2011). Particularly, amino acid 994 in the HECT domain is vital in causing causes the 
arrest of an early stage of viral assembly. The mutation of amino acid 994 to alanine 
causes the protein to lose its E3 ligase activity. Moreover, HERC5 has also been known 
to target newly synthesized proteins for ISGylation (Durfee et al. 2010). Our lab has 
shown that HERC5 is a vital protein in the inhibition of the budding process of HIV-1 
from the host cell, as well as the interference of unspliced viral RNA export (Woods et al. 
2011; Woods et al. 2014). 
1.3.1 ISGylation 
A protein sharing functional characteristics with Ubiquitin is referred to as a ubiquitin-
like molecule (UBL). One such molecule is a type 1 interferon induced 17 kDa secreted 
protein called ISG15 (Blomstrom et al. 1986). The conjugation of an ISG15 group to a 
substrate is referred to as ISGylation, a process very similar to ubiquitination. An ISG15-
specific interferon-induced E1 enzyme (UBE1L) attached and transfers a highly charged 
ISG15 group to an E2 protein (UbcH8). The E2 protein transports the ISG15 molecule to 
a particular E3 Ligase (HECT domain in HERC5) which subsequently recognizes and 
ligates the ISG15 onto relevant intracellular substrates (Figure 7). In fact, HERC5 is the 
major E3 ligase for ISGylation in human cells (Dastur et al. 2006). 
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Figure 7. Enzymatic E3-mediated conjugation of ISG15 to Gag protein. The E1 
enzyme (UbE1L) attached and transfers a highly charged ISG15 group to an E2 protein 
(UbcH8). The ISG15 if then transported to an E3 enzyme, where it can then be tagged on 
to a substrate. In ISGylation, the substrate is HIV-1, HERC5 acts as an E3 protein and 
tags the HIV-1 Gag protein with an ISG15 protein, thereby preventing budding on mature 
HIV-1 virions.  
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 ISGylation has the ability to impact diverse viruses. ISG15 conjugation is vital to 
an intrinsic antiviral response against HIV-1 (Morales & Lenschow 2013), where the 
level of ISG15 is correlated with viral load and CD4+ T-cells (Scagnolari et al. 2016). In 
HIV-1 Gag, ISG15 interferes with the interaction of the endosomal sorting cellular 
proteins, ESCRT-I with Tsg101, a protein that interacts with a motif on the Gag protein 
(Pincetic et al. 2010). ESCRT-I is responsible for recruiting ESCRT-II and ESCRT-III 
proteins which promote HIV viral budding (Votteler & Sundquist 2013). While in other 
viruses such as Influenza B, NS1 protein can inhibit the activation of the E1 enzyme and 
prevent ISGylation from occurring (Yuan & Krug 2001). Free ISG15 in cells is also able 
to inhibit proper ubiquitination of Ebola virus VP40 protein, thereby decreasing efficient 
release of VP40 virus-like particles from cells (Okumura et al. 2008). 
 
 Hypothesis and Aims  
A promising research field is the study of IFN induced antiviral proteins known as 
cellular restriction factors. Restriction factors are innate immune proteins that protect 
cells from viral pathogens (Jia et al. 2015). IFN stimulated genes such as HERC5 serve 
as one of the intimal defenses against viral infections. Despite the existence of IFN 
stimulated restriction factors, HIV-1 infection in individuals can persist, with the late 
stage of infection causing AIDS. Previously HERC5 has been shown to control viral 
replication by two independent mechanisms: inhibiting nuclear export of incompletely-
spliced HIV-1 RNA through the Rev-dependent pathway and blocking an early step in 
the assembly of the virion at the plasma membrane. Although HERC5 potently restricts 
HIV-1 in vitro, yet infected individuals fail to control HIV-1 replication even though 
HERC5 is highly expressed during acute and chronic infection (Woods et al. 2011; 
Woods et al. 2014).  
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  I hypothesized that HIV-1 possesses one or more proteins that antagonize the 
functions of HERC5. Understanding how HIV-1 antagonizes the functions of HERC5 
will provide further insight into how HIV-1 evades the interferon induced antiviral 
response. Therefore, the specific aim of this study was to identify and characterize HIV-1 
protein(s) that antagonizes the antiviral activity of HERC5. If an antagonist exists, 
follow-up aims was to develop molecular tools for studying whether the antagonist 
interacts (directly or indirectly) with HERC5 and elucidate the link between the sequence 
of the antagonist and its antagonistic ability.  
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Chapter 2  
2 Material and Methods  
 Cell culture 
Adherent HEK293T fibroblast cell lines were obtained from American Type Culture 
Collection. were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM). The media 
was supplemented with 10% fetal bovine serum (FBS), 100 U/ml Penicillin and 100 
g/ml Streptomycin (Sigma) in DMEM) at 37°C with 5% CO2.  
 
  Plasmids and Primers 
The following HIV-1 proteins were previously cloned into a pBAD vector: Vpu, Env 
(pIIIB), Env (pBaL), Nef, Vif, Tat. These vectors were obtained from Stephen Barr. The 
plasmid, pEGFP-Vpr was obtained through the NIH AIDS Reagent Program, Division of 
AIDS, NIAID, NIH (cat# 11386) from Dr. Warner C. Greene (Schaeffer et al. 2001). 
FLAG-tagged HERC5 (pHERC5) plasmid was kindly provided by Dr. K. Chin (Genome 
Institute of Singapore). HERC5 mutants (HERC5-ΔRLD, HERC5-RLD-only, HERC5-
ΔSpacer and HERC5-ΔHECT) were previously constructed by the Barr Lab using 
custom primers and site-directed mutagenesis, and cloned according to instructions in the 
Fast Cloning protocol described by Li et al. (2011). The GagPolRRE and Gag-CTE 
plasmids were generously provided by Dr. M. Malim (King’s College London).  
 
 Generation of HIV-1 Env mutants 
The pBaL plasmid was non-synonymously mutated using QuikChange II Site-Directed 
Mutagenesis Kit (Agilent), according to manufacturer’s instructions (Table 1, Table 2). 
Primers identified as “Bal mut all fwd” (5’AGACCCACCTCCCAACCCCG 
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GGGGGACCC GACAGGCCCGAAGGAATAGAAGAAG 3’) and “Bal mut all rev” 
(5’CTTCTTCTATTCCTTCGGGCCTGTCGGGTCCCCCCGGGGTTGGGAGGTGGG
TCT 3’) were used for the site directed mutagenesis and PCR amplification of the 
generated plasmid. Four amino acids (A723T, S724P, R725G, and G730E) in the 
cytoplasmic tail of gp41 were mutated to mimic the cytoplasmic domain of HIV-1 Env 
IIIB (Figure 8). Following mutagenesis, the PCR products were treated with DpnI (New 
England Biolabs) restriction enzyme (40 units per reaction) at 37°C for 60 minutes to 
digest the methylated supercoiled parental DNA (original template) and isolate our 
mutated DNA.  
The digested DNA was transformed in E. coli DH5α cells. 100 ng of DNA were 
added to 100 L of competent cells and incubated on ice for 30 minutes in a 1.7 mL 
Eppendorf tube. Following the incubation, the cells were heat shocked at 42°C for 100 
seconds and incubated on ice again for 10 minutes. 1 mL of LB media was added to the 
Eppendorf tube and the mixture was incubated in a 10xg shaker at 37°C for 60 minutes. 
The mixture was centrifuged at 4000xg for 5 minutes and 200 L of the mixture was 
plated onto LB + ampicillin agar plate and left overnight (16 hours) in a 5% CO2 
incubator at 37°C. Single colonies obtained from the ampicillin plates were picked and 
grown in 5 mL LB + 10 L ampicillin (100 M) overnight in a 10xg shaker at 37°C to 
screen for the vector with the given mutation. The following day, the bacteria was 
pelleted and DNA was extracted using Qiagen® plasmid mini kit, following 
manufacturer’s instructions. The DNA was quantified using a nanophotomoter and sent 
to be sequence verified at Robarts Research Institute. Verified mutants were grown in 
400 mL LB + 800 L ampicillin (100 M) and DNA prepped with Qiagen® plasmid 
maxi kit to be used to transfection. 
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Figure 8. A) Sequence alignment of the cytoplasmic domain in gp41 of two different 
Envelopes (BaL and IIIB). B) The highlighted nucleotides are the mutated bases in HIV-
1 Env gp41 pBaL to this area resemble HIV-1 Env IIIB. Mutations were induced in BaL 
to make the protein resemble HIV-1 Env IIIB. The residues mutated were A723T, S724P, 
R725G, and G730E (bottom). The cytoplasmic domain encompasses amino acids 712 to 
856 in HIV-1 Envelope.  
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Table 1. PCR amplification ingredients for the QuikChange II Site-Directed Mutagenesis 
Method 
5 L 10x Phusion HF buffer 
50 ng  dsDNA template (pBaL) 
1 L Phusion HF DNA polymerase 
125 ng  BaL mut all for 
125 ng  BaL mut all rev 
1 L dNTP mix 
X L ddH20 
50 L Total volume 
 
Table 2. PCR amplification parameters for the QuikChange II Site-Directed Mutagenesis 
Method 
Segment  # of Cycles  Temperature  Time  
Initial Denaturation 1 95°C 30 seconds 
Denaturation 18 95°C 30 seconds 
Annealing  18 55°C 1 minute  
Extension  18 68°C 6 minutes  
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 Env domain swap 
The Env protein domains (gp41 and gp120) were swapped using custom primers that 
encapsulated each domain of the protein. The gp120 and gp41 domains from each of the 
HIV-1 Env proteins (IIIB and BaL) were amplified separately for a total of 4 individual 
PCR reactions. The gp120 domain from IIIB was then PCR amplified together with the 
gp41 domain from BaL and the gp120 domain from BaL was PCR amplified together 
with the gp41 domain from IIIB, thereby “swapping” the domains from the two separate 
proteins. The following primers were used: “IIIBgp41swapforw” (5’ 
AGAGAGAAAAAAGAGCAGTGGGAATAGGAGC 3’), “IIIB120swaprev” (5’ 
CTCCTATTCCCACTGCTCTTTTTTCTCTCTGCA 3’), “BaLgp41swapforw” 
(5’AGAGAGAAAAAAGAGCAGTGGGAATAGGAGCT 3’), “BaL120swaprev” (5’ 
GCTCCTATTCCCACTGCTCTTTTTTCTCTCTGC 3’) (Figure 9). The PCR conditions 
utilized are outlined in Table 3 and Table 4.  
 Transfections 
293T cells were transfected using the Lipofectamine 2000 transfection reagent 
(Invitrogen) according to manufacturer’s instructions. For the viral antagonist assay, 
DNA was transfected at the ratio of 1:1:5:5 for GagPolRRE/GagPolCTE : HIV-1 
Rev:GL3/HERC5/ HERC6:HIV-1 gene.  
To examine the relevance of both Env domains (gp41 and gp120), we acquired 
HIV-1 Env sequences from Dr. Chen Liang from McGill University. The Env sequences 
are originally from patients in Thailand and India cloned into an expression vector and 
used to conduct the antagonist assay. Each individual sample contained an HIV-1 Env 
sequenced derived from a patient, which was then cloned into an expression vector. The 
sequences of both domains (gp120 and gp41) of HIV-1 Env varied between each sample. 
The sampled acquired are HIV-1 Subtype A, C or D (NIH-AIDS Reagent Program 
Catalog #11947, Lots: 120042, 130171). For the patient sample antagonist assay, DNA 
was transfected at the ratio of 1:5 for NL4-3 with patient Env : HERC5. 
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Figure 9. Schematic of the PCR conducted to create HIV-1 Env domain swapped 
proteins. The PCR fragment IIIB gp41 was added to the PCR fragment of Bal gp120 and 
the DNA were PCR amplified. Complimentary regions between the two domains allowed 
the two fragments (domains) to anneal to each other.  
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Table 3. Standard PCR amplification parameters 
Segment  # of Cycles  Temperature  Time  
Initial Denaturation 1 95°C 30 seconds 
Denaturation 30 95°C 30 seconds 
Primer Annealing  30 65°C 1 minute  
Extension  30 72°C 6 minutes  
Final Extension 1 72°C 5 minutes 
 
Table 4. Standard PCR amplification ingredients 
Volume Ingredient 
10 L 10x Phusion HF buffer 
1.5 L dNTPs 
1 L Forward primer 
1 L Reverse primer 
0.5 L Phusion HF polymerase 
100 ng Template DNA 
X L Milli-Q H20 
50 L Total  
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 Quantitative real-time PCR 
Total RNA was extracted from cell lysates using Pure Link RNA Mini Kit in 20 
L of RNAse free water, according to manufacturer’s instructions. 1000 ng of the total 
RNA was reverse transcribed using M-MLV reverse transcriptase (Life Technologies) 
Oligo(dT) primers (Life Technologies) according to manufacturer's instructions. The 
resulting cDNA was used as a template for quantitative PCR using the SYBR Green 
Probe Master Mix (Qiagen) and gene specific primers (Table 1). Prior to qPCR, cDNA 
samples were diluted 1:5 with water. Each reaction contained 10 L of SYBR Green 
Master Mix, 2 L of gene-specific primers (1 l of 10 M forward primer and 1 l of 10 
M reverse primer), 4 l of cDNA, and RNA free water to a total volume of 20 l. Real-
time PCR was carried out using QuantiStudio5 Applied Biosystems (Thermo Fisher 
Scientific). Quantification of Gag mRNA was conducted under the following cycling 
conditions: 2 min at 95°C and 40 cycles of 5 sec at 95°C, 10 sec at 60°C, and 20 sec at 
72°C. The QuantStudio Design and Analysis Desktop Software (version 1.4) was used to 
determine the CT for each PCR reaction. Threshold cycle (∆CT) values for the target RNA 
were normalized to the ∆CT values of GAPDH (control) and relative fold changes were 
calculated using the Pfaffl Equation (Pfaffl, 2001). The following primers were used: 
GAPDH - “GAPDH qPCR fwd” (5’ CATGTTCGTCATGGGTGTGAACCA 3’), 
“GAPDH qPCR rev” (5’ AGTGATGGCATGGACTGTGGTCAT 3’); Gag – “GagFwd-
qPCR” (5’ GTGTTTCAATTGTGGCAAAGAAGGG 3’), “GagRev-qPCR” (5’ 
CCTGTCTCTCAGTACAATCTTTCATTTGG 3’). 
 
 Co-immunoprecipitation  
Following transfection, cells were harvested, washed with ice-cold PBS and lysed 
with non-denaturing lysis buffer (1% (w/v) Triton X-100, 50 mM Tris-Cl pH 7.4, 5 mM 
EDTA pH 8.0, 300 mM NaCl, 0.02% (w/v) sodium azide with protease inhibitor (PI) 
(Roche Catalog Number 11697498001)) for 20 minutes. Cyanogen Bromide-activated 
Sepharose beads (GE Health Care) were swollen in 1 mM HCl for 10 minutes followed 
32 
 
by antibody coupling using 1 L of monoclonal HIV-1 mouse anti gp120 (NIH AIDS 
Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (902) 
from Dr. Bruce Chesebro) per 75 l of beads in coupling buffer (0.1 M NaHCO3 pH 8.3 
with 0.5 M NaCl) overnight at 4°C. Following the overnight incubation, the antibody 
conjugated beads were blocked with blocking buffer (0.1 M Tris-HCl buffer pH 8.0) 4°C 
for 2 hours. The blocking buffer prevents the non-specific binding of the antibodies to the 
membrane surface. After the blocking, the beads were washed with 3 cycles of 
alternating pH buffers (0.1 M sodium acetate pH = 4.0 with 0.5 M NaCl; 0.1 M Tris-HCl 
pH = 8.0 with 0.5 M NaCl). The cell lysates were then added to the conjugated beads for 
1 hour at 4°C. The beads were washed 5 times with non-denaturing lysis buffer and the 
protein was eluted in 60 L of 1 mM NaCl. 
 
 Western Blotting 
2.8.1 Collecting cell lysate and virus 
Cell pellets from 12 well plates were collected in the cell culture media (DMEM) 
and centrifuged at 2000 x g for 10 minutes. Clarified supernatants from centrifuged cell 
pellets containing virus particles were pelleted over a 20% sucrose cushion for 2 hours at 
21,000 × g and lysed with RIPA (Radioimmunoprecipitation assay) buffer (10 mM Tris-
Cl pH = 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 
mM NaCl), alongside 10% PMSF (phenylmethylsulfonyl fluoride) (final concentration of 
1 mM), a serine protease inhibitor, and 10% PI (protease inhibitor) (final concentration of 
1 mM) for quantitative Western blot analysis. The cell pellets for each condition were 
kept on ice also lysed using the RIPA lysis buffer concoction.  
To prepare a 10% polyacrylamide resolving gel, 1.5 M Tris (pH = 8.8), 
ammonium persulfate, 10% SDS, TEMED and 30% Acrylamide/Bis Solution, 29:1 (Bio-
Rad Laboratories Cat #1610156) were mixed together. The stacking gel used an identical 
recipe and substituted 1.0 M Tris (pH = 6.8) for 1.5 M Tris (pH = 8.8). Before running, 
4x protein dye (Lamelli buffer) with 5% β-mercaptoethanol was added to the samples and 
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the samples were heated and denatured for 10 minutes at 98°C. Post denaturing, the 
samples were loaded into the gel alongside the ladder and ran at 120 V for 1.5 hours. 
After the run, the gel was transferred onto a Polyvinylidene difluoride (PVDF) membrane 
(GE Healthcare) at 18 V for 1 hour. Finally, the membrane was blocked using Odyssey 
Blocking Buffer (LI-COR Biosciences) at room temperature for 1 hour and incubated 
with the appropriate antibody overnight (~16 hours) at 4°C on a shaker. The following 
day the blot was washed 3 times with a Tween based wash buffer (137 mM NaCl, 2.7 
mM KCl, 4.3 mM Na2HPO4∙7H2O, 1.4 mM KH2PO4, 0.1% Tween) and incubated with 
the corresponding secondary antibody for 1 hour. The membrane was then washed 3 
times with Tween wash buffer and visualized using the Odyssey CLx (LI-COR 
Biosciences). The following primary antibodies were used: HERC5- anti-FLAG (1:1000) 
from Sigma; HIV-1 Env gp120- anti-gp120 (1:750) from NIH AIDS Reagent; cellular 
GAPDH- anti-GAPDH (1:20000) from EMD Millipore Corp, HIV-1 Gag protein- anti-
HIV-1 p24 (1:1000) Monoclonal Antibody (183-H12-5C) from Dr. Bruce Chesebro and 
Kathy Wehrly (Wehrly & Chesebro 1997; Toohey et al. 1995; Chesebro et al. 1992). 
Secondary rabbit IRDye 680 secondary antibody (LiCOR) (1:10000) was used to 
visualize FLAG tagged HERC5, secondary mouse IRDye 800 antibody (LiCOR) 
(1:10000) was used to identify bound HIV-1 p24 and our transfection control, GAPDH.  
 
 Statistical analyses 
Western blot data were acquired using ImageStudio (LI-COR Biosciences) and 
densitometric analysis conducted using ImageJ. Data from Image J and qPCR analysis 
was statistically analyzed by utilizing GraphPad Prism v6.0. P values and statistical tests 
used are indicated where appropriate. 
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Chapter 3 
3 Results 
 
 Comparing anti-HIV activity of HERC family members  
It was previously shown that HERC5 inhibits Rev-dependent nuclear export (Woods et 
al. 2014). However, it is unknown if other members of the small HERC family of 
proteins share this activity. The HIV-1 unspliced mRNA is transported through the 
CRM1 pathway from the nucleus to the cytoplasm. The export of unspliced HIV-1 RNA 
is driven by the RNA binding protein, Rev, which upon binding to the RRE stem-loop 
structure, enables the export of intron-containing HIV-1 RNA from the nucleus to the 
cytoplasm through the CRM1 pathway.  
First, I wanted to test the inhibitory effect of HERC5 on Gag protein production 
in transfected 293T cells and optimize transfection conditions for subsequent 
experiments. To test if HERC5 inhibits Gag protein production, I used an established 
nuclear export assay where 293T cells were co transfected with HERC5 and a plasmid 
containing Rev-dependent HIV-1 Gag (pGagPolRRE) (Woods et al. 2014). Viral particle 
production was quantified by measuring HIV-1 Gag protein (Pr55 Gag), while using 
Actin as a loading control. 293T cells were co-transfected with a plasmid encoding Rev, 
pGagPolRRE and increasing concentrations of a plasmid encoding HERC5. Forty-eight 
hours post transfection, the protein lysate was utilized for Western Blot analysis (Figure 
10). 
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Figure 10. HERC5 inhibits Rev dependent transport. Gag protein production in 293T 
cells when transfected with pGagPolRRE: HERC5. A plasmid encoding FLAG-tagged 
HERC5 is transfected in increasing amounts to visualize concentration dependent effects 
of HERC5 on HIV-1 particle release. Particle release is measured by examining the 
protein levels of Gag protein (Pr55Gag). Actin was used as a loading control. The 
western blots were probed with primary mouse anti-p24CA and rabbit anti-ß-Actin.   
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 The HERC5 protein is from the HERC family of genes shown to be involved in 
ISGylation (Oudshoorn et al. 2012; Paparisto et al. 2018). Given that HERC5 likely 
originated from a duplication event in HERC6 (Hochrainer et al. 2005), testing the other 
HERC proteins allowed us to determine if related HERC proteins contained any antiviral 
activity. For the quantitative measure of viral particle production, we measured HIV-1 
Gag levels by western blot using anti-p24CA and normalized the Gag protein levels to 
the actin (loading control) (Figure 11B). To keep the total DNA constant between 
conditions, an empty vector was used. When there was no HERC5 co-transfected with 
GagPolRRE, a large amount of Gag protein was produced. But as we increased the 
amount of HERC5 added, Gag protein decreased in a dose-dependent manner. This assay 
demonstrated that Gag protein production is inhibited when HERC5 is expressed (Figure 
11C). Consistent with the previous findings of our lab (Woods et al. 2014), in the 
absence of HERC5, the maximum amount of Gag protein is produced 
To determine if HERC3, HERC4 and HERC6 also blocked nuclear export of Rev-
dependent HIV-1 RNAs, we co-transfected 293T cells with plasmids encoding full-length 
HIV-1 R9 and either empty vector, HERC3, HERC4, HERC5 or HERC6. Total RNA 
was harvested from total cell extract or cytoplasmic extract only and subjected to 
Quantitative Real-time PCR (qPCR) with primers specific to either Gag (unspliced HIV-
1 genomic RNA), or β-actin (loading control). Each of the small HERC proteins caused 
significant reduction in the amount of HIV-1 RNA present in the cytoplasm, and HERC5 
caused the largest reduction in HIV-1 Gag RNA (Figure 11A).  
To further support this finding, we tested the ability of the small HERCs to inhibit 
nuclear export of Rev-dependent Gag RNA. HIV-1 Rev promotes nuclear export of 
incompletely spliced HIV-1 mRNAs by binding to a specific cis-acting element called the 
rev-response element (RRE), located within an HIV-1 intron. Successful export of 
incompletely spliced RNA can be assessed by Western blotting for Gag protein 
expression. 293T cells were co-transfected with a plasmid encoding Rev and increasing 
concentrations of plasmids encoding HERC, with pGagPol-RRE.  
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Figure 11. HERC5 restricts Gag RNA and protein. 293T cells were co- transfected 
with increasing amounts of plasmids encoding HERC3, HERC4, HERC5 or HERC6 and 
Rev-dependent GagPol-RRE (+ pRev). Total DNA transfected was kept equal with 
empty vector plasmid. A) Total RNA was harvested and HIV-1 Gag RNA was quantified 
using qPCR. B) Gag protein levels within the cell lysates were analyzed by quantitative 
Western blotting using anti-p24 (Gag) and anti-actin as a loading control. C) Fold change 
of Gag protein was quantified by densitometric analysis of the western blot. Statistical 
significance was determined using ANOVA with Dunnett’s multiple comparisons test 
with respect to the control; * P <0.05, ** P <0.01, *** P <0.001. 
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As shown in Figure 11B and 11C each of the small HERCs differentially 
inhibited nuclear export of Rev-dependent RNA, where HERC5 exhibited the highest 
level of inhibition and HERC6 the weakest inhibition. Together, these findings indicate 
that the small HERC members differentially inhibit nuclear export of Rev-dependent 
RNAs. 
 HIV-1 Env IIIB antagonizes HERC5 
The viral release assay outlined in the previous figure showed that HERC5 is able to 
inhibit the production of HIV-1 Gag particles in vitro (Figure 11C). However, when we 
measured Gag RNA levels in an experiment with HERC5 and HIV-1 lab adapted strain 
R9, there was still some production of HIV-1 Gag RNA despite the significant decrease 
caused by HERC5 (Figure 11A). Furthermore, HERC5 is still expressed in HIV-1 
infected patients, despite its potent activity in vitro. I hypothesized that this is likely due 
in part to the antagonistic ability of HIV-1 proteins that oppose antiviral actions of 
restriction factors. To determine if certain HIV-1 proteins could antagonize HERC5, 
293T cells were co-transfected with a plasmid carrying HERC5 and different plasmids 
containing an HIV-1 protein (Nef, Vpu, Env, Vif, Vpr, or Tat). The proteins were 
individually co-transfected with HERC5 to determine if the proteins could rescue Gag 
protein production. When GagPolRRE is transfected with our empty vector control, there 
is a copious amount of Gag protein produced. However, the introduction of HERC5 
hinders the protein production of Gag (Figure 11). In theory, if an HIV-1 protein 
antagonizes the function(s) of HERC5, a rescue in Gag protein in the supernatant and/or 
Gag RNA in the cell pellet should be observable.  
We first examined the effect of HIV-1 Nef, Env (IIIB) or Env (BaL) on HERC5 
antagonism. The envelope proteins we tested were from different strains of HIV-1, where 
IIIB was X4 tropic and BaL was R5 tropic, meaning there was some sequence variation 
between the two Env proteins. 293T cells were co-transfected with plasmids carrying 
HERC5 and either Env (IIIB), Env (BaL) or Nef. Gag protein was measured by Western 
blotting. The fold change corresponds to the total amount of Gag protein produced after 
normalization to our control condition.  
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In the presence of HERC5 there was a significant decrease in the Gag protein 
expression, consistent with previous findings (Woods et al. 2014) (Figure 12). 
Strikingly, there was a significant increase in the level of Gag expression when HIV-1 
Env (IIIB) was co-transfected with HERC5. In contrast, the BaL variant of HIV-1 Env 
did not rescue Gag protein levels. Moreover, HIV-1 Nef, similar to HIV-1 Env (BaL) was 
not able to rescue Gag protein levels. Both HIV-1 Env (BaL) and HIV-1 Nef Gag fold 
change was comparable to our HERC5 condition and significantly less than the empty 
vector control condition (Figure 12). The addition of HIV-1 Env (IIIB) to HERC5 
correlated with a significantly higher amount of Gag protein produced in the presence of 
HERC5, indicating a potential antagonistic function for HIV-1 Env (IIIB). A shortfall of 
this experiment was the lack of a loading control for the viral supernatant. Because the 
Gag p24 was harvested from the viral particles that were not intracellular, we were 
unable to use a protein such as GAPDH or Actin as a loading control that normalizes the 
loaded protein in each well.  
We previously showed that HERC5 can inhibit nuclear export of Rev dependent 
(Gag) RNAs (Woods et al. 2014). To determine if Env (IIIB) rescued Gag RNA levels, 
we utilized the aforementioned Rev-dependent nuclear export assay. Total RNA was 
extracted from the 293T cells 48 hours post transfection and examined using qPCR with 
primers specific to either Gag or GAPDH. Not only was Gag RNA production rescued in 
the presence of HIV-1 IIIB Env, but compared to HERC5, there was a 2.5-fold increase 
in the level of Gag produced. The pattern we observed in the co-transfection of BaL and 
HERC5 correlated with our previous Western blot data. BaL did not antagonize the 
function of HERC5, whereas HERC5 expressed in the presence of HIV-1 Env IIIB 
produced a significantly greater level of Gag protein production (fold change) compared 
to our HERC5. This difference, however, was not significantly greater than our control 
condition (Figure 13). Each condition was normalized to cellular GAPDH levels and 
compared to our empty vector control.  
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Figure 12. HIV-1 Env rescues Gag protein level. 293T cells were transfected for 48 
hours with plasmids carrying GagPolRRE, Rev, and HERC5. In addition, a plasmid 
carrying a HIV-1 Env (IIIB), Env (BaL), or Nef was added to test antagonism. If Gag 
protein recovers when HERC5 is co-transfected with an HIV-1 protein, it indicates 
HERC5 is being antagonised. A) Following this, the supernatant (containing Gag 
particles) was collected and ran on a Western Blot. Shown is the mean fold change 
(+SEM) of Gag protein production in 293T cells. B) The fold change was calculated by 
densitometric analysis of Western blots and comparing Gag protein produced in each 
condition to the control. The control was an empty vector co-transfected with Rev and 
GagPolRRE. HIV-1 Nef was not able to rescue Gag protein production. The HIV-1 IIIB 
variant (X4) and BaL (R5) variants of Env were both tested as possible antagonists to 
HERC5. HERC5 only was used as a positive control given its established ability to 
hinder HIV replication. These data represent the average fold change (+SEM) of 3 
independent experiments. ****P<0.0001; One-way ANOVA, Dunnett’s multiple 
comparisons test, n = 3.  
 
+HERC5
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Figure 13. Env rescues Gag RNA produced in presence of HERC5. 293T cells were 
transfected for 48 hours with plasmids carrying GagPolRRE, Rev, and HERC5. In 
addition, a plasmid carrying a HIV-1 Env (IIIB), Env (BaL), or Nef was added to test 
antagonism. 48 hours post transfection, the cells were lysed to collect RNA. Quantitative 
PCR was conducted to calculate the total amount of Gag RNA produced intracellularly. 
These data represent the average fold change (+SEM) of 3 independent experiments after 
normalization to GAPDH levels. *P<0.05. One-way ANOVA, Tukey’s test, n = 3. 
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The ability of HERC5 to inhibit nuclear export of HIV-1 RNAs and assembly of 
particles at the plasma membrane begs the question of which function was the antagonist 
targeting. It was important to do both a qPCR and a Western blot as the western blot 
assay provided us with a clear picture of VLPs (Gag protein) released while the qPCR 
provided us with an accurate measure of Gag RNA level.  
 
 HIV-1 Vpu antagonizes HERC5 
HIV-1 proteins, such as Vpu and Vif have been previously shown to exhibit some 
antagonist ability towards restriction factors and therefore were worthwhile candidates 
for testing antagonistic ability towards HERC5 (Yu et al. 2003; Beitari et al. 2017; Rosa 
et al. 2015). In this particular experiment, we determined if Vpu, Vif or Vpr, could 
antagonize HERC5 (Figure 14). The experimental protocol was identical to the one used 
for HIV-1 Env, but Env substituted for other accessory proteins. The supernatant contains 
virus-like particles (VLPs) that were ran on a western blot and probed with anti-p24 (Gag 
protein). Gag protein particles produced in each condition were quantified through 
densitometric analysis and compared to our control (empty vector co-transfected with 
Rev and GagPolRRE). As expected, the level of Gag protein particles decreased 
significantly in the presence of HERC5 plasmid, compared to our control (empty vector 
co-transfected with Rev and GagPolRRE) (Figure 14). When HERC5 is co-expressed 
with HIV-1 Vpu (Vpu + HERC5), we see a significant difference in the expression of 
Gag protein in the transfected cells compared to cells expressing HERC5 only. The same 
Gag protein production is not apparent when other HIV-1 proteins such as Vif, or Vpr are 
co-transfected with HERC5. It should be noted that the fold change of Vpu + HERC5 is 
not significantly different compared to our control (Figure 14).  
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Figure 14. HIV-1 Vpu rescues Gag protein level. 293T cells were transfected for 48 
hours with plasmids carrying GagPolRRE, Rev, and HERC5. In addition, a plasmid 
carrying a HIV-1 Vpu, Vif or Vpr was added to test antagonism. Following this, the 
supernatant was collected and used to conduct a Western Blot (data not shown). The fold 
change was calculated by comparing Gag protein produced in each condition to the 
control (no HERC5). Mean fold change (+SEM) of Gag protein production in 293T cells. 
HIV-1 Vpu, Vif, and Vpr were all tested as possible antagonists to HERC5. These data 
represent the average fold change (+SEM) of 3 independent experiments. *P<0.05; 
***P<0.001 One-way ANOVA, Tukey’s test, n = 3.  
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Similar to our previous experiments, it was also important to analyze the effect of 
HERC5 antagonism on HIV-1 Gag RNA. In this assay, HIV-1 Gag RNA was again 
significantly decreased when HERC5 was introduced into the cells compared to our 
control (no HERC5). When HIV-1 Vpu was co-expressed with HERC5, there was a 
significant increase in the Gag RNA levels compared to HERC5 expression alone, and no 
significant difference when comparing the HERC5 + Vpu condition with the control 
(Figure 15). This data indicates the possibility of HIV-1 Vpu as a potential antagonist of 
HERC5 function. HERC5’s dual restrictive ability (block of Rev-dependant export and 
viral assembly), each assay provides a unique insight as to which mechanism is being 
inhibited. The rescue of Gag RNA in the cell lysate could indicate antagonism of the 
HERC5 nuclear export mechanism while a rescue in VLP production in the supernatant 
could indicate antagonism of both the ISGylation and nuclear export mechanism. 
Altogether, this showed that Vpu is capable of antagonizing HERC5 activity.  
 
 HERC5 potentially interacts with Env 
To determine if HERC interacts with Env, we expressed HIV-1 Env (IIIB) only, FLAG-
tagged HERC5 only or Env (IIIB) and FLAG-tagged HERC5 for 48 hours in 293T cells. 
Cells were collected, lysed and incubated with sepharose beads conjugated with mouse 
anti-FLAG to pull down HERC5 and interacting proteins. Following the co-IP, we 
probed the Western blot with anti-FLAG and anti-HIV-1 Env gp120. Since the flag 
tagged HERC5 and Env proteins are both approximately 120 kDa, one band would 
overlay the other and we would be unable to tell conclusively if in fact an interaction 
between Env gp120 and HERC5 was occurring. Therefore, during the co-IP process, 
samples were treated with PNGase F to decrease the size of Env from 120 kDa to 80 kDa. 
PNGase F removes high-mannose N-linked oligosaccharides from glycoproteins, thereby 
decreasing the total size of the protein.  
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Figure 15. HIV-1 Vpu rescues Gag RNA. 293T cells were transfected for 48 hours with 
plasmids carrying GagPolRRE, Rev, and HERC5. In addition, a plasmid carrying HIV-1 
Vpu was added to test antagonism. Forty-eight hours post transfection, the cells were 
lysed to collect RNA. Quantitative PCR was conducted to calculate the total amount of 
Gag RNA produced intracellularly. These data represent the average fold change (+SEM) 
of 3 independent experiments after normalization to GAPDH levels. **P<0.05, 
***P<0.01. One-way ANOVA, Tukey’s test. n = 3.  
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In the lane labelled “HERC5 + IIIB”, there is only one band present around the 
120 kDa position, indicating although HERC5 is present, HIV-1 Env is absent (Figure 
16). The input lanes serve as a control for the co-IP as they are just cell lysates from each 
transfection condition, thereby the presence of a band in the input lanes indicates that the 
samples used contained the target protein. The presence of a band in the 120 kDa region 
indicated the conjugated antibody pulled down the FLAG tagged HERC5 protein. It 
should also be noted that the expected band in our “IIIB” input lane was absent, 
indicating that the control did not work. The expected position of the Env band should be 
around the 80 kDA area. The absence of a band in the input lane could also indicate that 
not enough protein was loaded and the protein of interest is only expressed in low levels. 
Therefore, additional experiments are necessary to determine if HERC5 and HIV-1 Env 
gp120 interact. 
 
 The effect of the Env sequence on antagonism  
3.5.1 Mutated Env (BaL) does not rescue viral protein production   
Lodged into the host cell membrane, the gp41 the transmembrane component is anchored 
to an area called “the cytoplasmic tail” which is exposed to the cytoplasm of the host cell. 
Aligning the sequences of HIV-1 Env, (IIIB and BaL) revealed 5 non-homologous amino 
acid differences in the gp41 cytoplasmic domain of the proteins. Our rationale was that if 
an interaction occurred that caused antagonism it would be at the cytoplasmic domain, 
one of the few areas of Env was exposed to the cytoplasm and most accessible to HERC5 
interaction. To identify the amino acid determinants in the HIV-1 Env responsible for 
antagonism, I planned to swap the gp41 domains of the IIIB and BaL proteins.  
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Figure 16. Co-IP of gp120 and HERC5. 293T cells were transfected with either a 
plasmid carrying HIV-1 Env (IIIB), a plasmid carrying FLAG-tagged HERC5, or co-
transfected with a HERC5 plasmid carrying HIV-1 Env (IIIB). Each condition was 
treated with PNGase F and co-immunoprecipitated to pull down proteins bound to 
sepharose beads conjugated to anti-FLAG. The samples were separated using SDS-
PAGE and subject to Western blot analysis using mouse anti-FLAG and mouse anti-
gp120. Although the size of gp120 is 120 kDa, the PNGase treatment decreases the size 
of the protein to 80 kDa. “kDa” on the protein ladder refers to the kilodaltons. The input 
lanes were cell lysates not conjugated with beads and served as positive controls. Each 
lane had 30 L out of 60L total lysate loaded (50%).  
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In parallel, I also performed a more targeted approach to identify specific amino 
acids involved in the antagonism. Using site directed mutagenesis, I mutated 4 proximal 
amino acids in the gp41 cytoplasmic domain in BaL (A723T, S724P, R725G, and 
G730E) to mimic the amino acids in IIIB while keeping the rest of the protein 
homologous. This mutant protein is referred to as “BaL mut”. These amino acids are 
contained within the cytoplasmic tail and are non-homologous amino acid differences 
between IIIB and BaL. These amino acids were thought to be significant because of the 
interaction of the gp41 cytoplasmic tail with the host cell cytoplasm.  
 HERC5, as expected, severely decreased the Gag protein production compared to 
our control. The analysis of the viral supernatant indicated that co-expressing WT Env 
IIIB with HERC5 rescued viral particle production, as shown previously while co-
expression of WT Env BaL and HERC5 did not seem to affect Gag protein fold change 
compared to the control. Since the viral supernatant is the amount of viral particles 
released outside of the cell, it is difficult to normalize the data using a loading control 
such as GAPDH or actin. Although IIIB is able to antagonize the function of HERC5, the 
4-amino acid mutation in the cytoplasmic tail of gp41 (Bal mut) did not fully rescue Gag 
protein production, indicating there might be more factors involved in the Env mediated 
antagonistic mechanism (Figure 17). It should be noted that this assay was only 
conducted twice and therefore the fold change produced by the introduction of BaL mut 
could not be ruled as significantly different. Therefore, more replicates are needed to 
statistically analyze the data in order to determine significance.  
I also looked at the Gag RNA produced in the presence of the mutated BaL 
protein. HERC5 inhibited production of HIV-1 Gag mRNA as expected. Moreover, the 
co-expression of Env IIIB with HERC5 rescued viral RNA production, (as shown 
previously) while the co-expression of BaL and HERC5 did not seem to affect Gag RNA 
fold change compared to the control. 
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Figure 17. Bal mut does not rescue Gag protein production. A) Viral antagonist assay 
conducted in 293T cells transfected for 48 hours with variants of HIV-1 Env co-
transfected with plasmids carrying HERC5, GagPolRRE and Rev. Following this, the 
supernatant was collected and ran on a Western blot. B) The fold change was calculated 
by densitometric analysis of Western Blots, followed by comparison of Gag protein 
produced in each condition to the control (no HERC5). HERC5 only was used as a 
positive control given its established ability to hinder HIV replication. These data 
represent the average fold change (+SEM) of 2 independent experiments, n = 2  
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 Consistent with the Western Blot data, the co-expression of BaL mut with 
HERC5 did not rescue Gag RNA production compared to our control. When Bal mut was 
co-expressed with HERC5, the amount of Gag RNA produced was far compared to the 
co-expression of HIV-1 Env IIIB and HERC5. Lastly, when BaL was co transfected with 
HERC5, there was no substantial production of Gag RNA, consistent with our previous 
results (Figure 18). Overall our assays with the mutant BaL protein indicate that amino 
acids, (A723, S724, R725, and G730), of the cytoplasmic domain of gp41 are not solely 
responsible for the antagonism of HERC5 by HIV-1 Env (IIIB). 
3.5.2 Swapping gp120/gp41 domains 
To determine if the entire gp41 domain of Env IIIB can confer antagonistic activity 
against HERC5, I used PCR mutagenesis to swap the domains the Env IIIB and Env BaL 
(Figure 19). Creating this swap product involved PCR amplifying each region separately 
and combining them with the region from the corresponding Env. To do this, we PCR 
amplified both domains separately using custom primers. The gp120 domain of HIV-1 
envelope and the gp41 domains were amplified in 4 individual PCR reactions. We then 
took two of the PCR products and combined them (i.e. IIIB gp41 combined with BaL 
gp120 and IIIB gp120 combined with BaL gp41) to generate unique Env proteins 
(Figure 19). 
The DNA sequence of the gp120 domain is 1500 bp while the gp41 encompasses 
the remaining 1000 bp to generate a ~2500 bp sequence. Therefore, we expected bands to 
be around those regions. The presence of the band around the 1000 and 1500 bp regions 
in the first four lanes indicate the successful amplification of each domain while the 
presence of the 2500 bp band in the final two lanes indicates the successful creation of 
the newly manufactured, combined Env protein (Figure 9, Figure 19). Although these 
plasmids were generated, future studies will be conducted to analyze these mutant 
proteins in an antagonistic assay.  
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Figure 18. Bal mut does not rescue Gag RNA production. qPCR results 293T cells 
transfected with plasmids containing HERC5 (H5), Rev and GagPolRRE, with or without 
different variants of HIV-1 Env. Forty-eight hours post transfection, the cells were lysed 
and total RNA was harvested. qPCR was conducted to quantify the total amount of Gag 
RNA produced intracellularly and compared to our control (no HERC5). These data 
represent the average fold change (+SEM) of 2 independent experiments after 
normalization to GAPDH levels, n = 2. 
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Figure 19. Construction of Env domain mutants. The gp41 from BaL was connected 
to the gp120 from IIIB and vice versa. Gel electrophoresis of PCR amplifications of the 
two domains of HIV-1 envelope (gp120 and gp41). Each domain was individually 
amplified from each Env (i.e. IIIB gp120) and combined with the domain from the other 
Env (i.e. BaL gp41) to generate a swap mutant. The size of gp120 was expected to be 
approximately 1500 bp while gp41 is 1000 bp. The 0.5% agarose gel was ran at 120V for 
30 min and visualized using UV light. The primers used in the experiment were designed 
to flank the Env domains (gp41 and gp120) so they could be amplified.  
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Although I was successful in generating and inserting the mutated DNA into the 
pcDNA 3.1+ plasmid, due to time constraints the follow up experiments will be 
conducted in future studies. These studies will entail the co-transfection of plasmids 
carrying the HIV-1 domain swap mutants and HERC5 into 293T cell and qualifying viral 
particle release using western blotting and Gag RNA levels using qPCR as described in 
section 3.5.1.  
 
 Differential antagonism of HERC5 using patient derived 
HIV-1 Env sequences  
293T cells were co-transfected with plasmids containing independent derived HIV-1 Env 
sequences form HIV infected patients, HERC5, and the pGagPol-RRE expression vector. 
The 5 patients we examined were chosen randomly from a total of 19 different patients of 
HIV-1 Subtype A, C or D. The addition of a vector containing a varying envelope protein 
will elucidate if particular amino acid residues in HIV-1 Env are responsible for the 
antagonism of HERC5. Antagonism will be assessed by the assay outlined in Section 3.2. 
Successful export of incompletely spliced RNA was assessed by Western blotting for 
Gag protein expression after the viral supernatant, (which contained released VLPs) was 
harvested 48 hours later. 
The samples were analyzed using Western blot (data not shown) and 
densitometric analysis was utilized to quantify Gag protein in the supernatant. Out of the 
5 patients we were able to screen, one patient in particular stood out after the first trial, 
patient #11887. Despite the presence of HERC5, they still exhibited copious amount of 
Gag production, indicating potent antagonistic ability (Figure 20), while the other 
patients showed presence of Gag protein. These data show that sequence variation in 
HIV-1 Env affects its ability to antagonize HERC5. The amino acid sequences for these 
patients were obtained using NIH AIDS Reagent and NCBI. Even in the initial 400 
amino acids, there exists a high degree of diversity between each patient envelope protein 
(Figure 21).  
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Figure 20. Antagonistic effects of patient derived HIV-1 Env proteins towards 
HERC5. Viral antagonist assay conducted in 293T cells transfected with plasmids 
containing HERC5, Rev and GagPolRRE, with different variants of HIV-1 Env derived 
from patients. The supernatant was collected and ran on a Western blot. The fold change 
was calculated by densitometric analysis of Western Blots, followed by comparison of 
Gag protein produced in each condition to the control (no HERC5). HERC5 only was 
used as a positive control given its established ability to hinder HIV replication. These 
data represent the average fold change (+SEM) of 2 independent experiments, n = 2 
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Figure 21. Comparing the first 400 amino acids in sequences of HIV-1 envelope 
from infected patients aligned using HIV-1 Env IIIB as the reference sequence. 
Sequences were aligned using the Multiple Sequence Alignment tool, MView (Brown et 
al. 1998). The index on the left side of the sequence indicated the percentage similarity to 
the query sequence (IIIB).   
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Chapter 4 
4 Discussion and Future Directions  
HERC5 is an ubiquitously expressed 117kDa protein expressed in primary cells and 
upregulated by Type I interferon. HERC5 expression levels are upregulated in response 
to viral infection in a host, but despite the existence of this antiviral protein and other 
similar restriction factors, viral infection in hosts does not dissipate and in fact, worsens. 
Here we identify HIV-1 Env and Vpu as potential antagonists of HERC5.  
To be classified a restriction factor, an antagonistic protein that can counteract or 
elude the antiviral activity of the host restriction factor must be present (Duggal et al. 
2012). A prime example of the fulfillment of these criteria is the cellular restriction 
factor, Tetherin. Tetherin is known to sequester virus release by causing the retention of 
mature, budding virions on infected cell surfaces. The envelope protein in HIV-2 
counteracts Tetherin-mediated restriction by altering the trafficking of Tetherin and 
excluding it from virus assembly sites on the plasma membrane. (Exline et al. 2015). In 
other restriction factors, HIV-1 Env was found to overcome the antiviral activity 
conferred by the SERINC5 protein (Beitari et al. 2017). KSHV (Kaposi’s sarcoma-
associated herpesvirus) produces viral interferon Regulatory Factors, (vIRFS), which 
down-regulates HERC5 mediated ISG15 conjugation, thereby providing a mechanism for 
the virus to evade the adaptive immune response (Jacobs et al. 2015). We have shown 
that HIV-1 envelope can antagonize the function of HERC5. Specifically, the envelope 
protein from the HIV-1 IIIB strain, along with HIV-1 Vpu can thwart the restrictive 
function of HIV and rescue Gag protein production levels (Figure 12, 14).  
Despite the first age estimate for zoonotic HIV-1 transmission being the year 
1963, SIV has existed as a persistent infection in non-human primates long before the 
transmission to humans (Wertheim & Worobey 2009). The genome of HIV-1 groups O 
and P is closely related to SIV from non-human primates (Figure 1) (Van Heuverswyn et 
al. 2006). Because of this, a large degree of functional and sequence homology is shared 
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between the proteins of the HIV and SIV, i.e Nef, Env, Gag. Similarly, viral antagonists 
encoded in the SIV genomes oppose the restriction factors that are present in the simian 
host immune systems. Antagonism results from the ability of viruses to evolve quicker 
than the hosts they occupy. In primates (including humans), the innate immune system is 
designed to defend against ancient pathogens rather than novel, emerging viruses. 
Though the host is well equipped to defend against older pathogens, it can suffer when 
defending against newer viruses when it comes to restriction factors. Therefore, the 
evolutionary history of restriction factors serves as an explanation for why humans are 
vulnerable to modern virus, such as HIV-1 or why these modern viruses can overcome 
host innate immunity (Duggal et al. 2012). 
The Red Queen’s hypothesis states that there is a dynamic co-evolution, or an 
evolutionary arms race that exists between the host and the pathogen (Clarke et al. 1994). 
The emergence of a novel antagonist for HERC5 is an exemplification of this hypothesis. 
When a pathogen such as HIV invades a host, the immune system fights back using 
innate antiviral proteins (restriction factors). This creates a dynamic co-evolution 
between the host and pathogen, where each attempts to get an advantage over the other. 
Therefore, to adapt, HIV counteracts restriction factors using viral antagonists. This 
occurs because just like the host, the virus is also trying to survive. One organism tries to 
outcompete the other in order to survive and pass on its genes. Just as the host (immune 
system) places barriers (restriction factors) to restrict the replication of the pathogen 
(HIV), the virus implements techniques to circumvent these obstacles (Harris et al. 
2012).  
Restriction factors provide an innate, host defensive mechanism against pathogens 
(Raposo et al. 2014). Evolutionary studies indicate that innate immunity may serve as an 
integral component in preventing cross-species viral transmission (Kirmaier et al. 2014). 
This is supported by the fact that some IFN stimulated genes are conserved in the genome 
and positively selected for in evolution (Schneider et al. 2014). Therefore, since these 
proteins confer a positive advantage to host survival, restriction factors are positively 
selected and evolutionary conserved. 
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This dynamic host/pathogen arms race is also apparent in viruses related to HIV-
1. For example, the antiviral activity of BST2/Tetherin is antagonized by the HIV-1 Vpu 
protein (Neil et al. 2009) but since HIV-2 lacks Vpu, the Env protein confers the same 
antagonism (Le Tortorec & Neil, 2009). In SIV, BST2/Tetherin is antagonized by the 27 
kDa Nef protein (Jia et al. 2009). Therefore, the shared presence of restriction factors 
among related primates may allow for the related viruses to overcome the anti-viral 
function of restriction factors. If an antagonist exists in a related virus, i.e. SIV antagonist 
for Tetherin, it may indicate that antagonism of host restriction factors by viruses is 
conserved.  
In my thesis, I investigated the possibility of an HIV-1 antagonist to the restriction 
factor HERC5. Previous results from our lab demonstrated HERC5’s ability to hinder 
viral release and replication through two independent mechanisms: HIV-1 unspliced 
mRNA export is inhibited by the potential disruption of the RanGTP gradient in the cell 
by the HERC5 RLD (Woods et al. 2014) while the HECT domain blocks mature virion 
formation by conjugating an ISG15 group to the HIV-1 Gag protein.  The CRM1 nuclear 
export pathway is regulated by the gradient of RanGTP. An optimal ratio of RanGDP to 
RanGTP needs to be maintained in the cell to ensure the proper function of CRM1 
mediated export (Melchior 2001; Behrens et al. 2017).  
Our results demonstrated that HIV-1 Env from the strain, IIIB antagonized 
HERC5 and fully rescued viral particle production, while the Env from the other strain, 
BaL, was unable to affect Gag protein production in a significant way. The restoration of 
Gag protein production in the viral supernatant and Gag RNA rescue in the cell pellet 
revealed HIV-1 Envelope IIIB as a prime candidate for antagonism of HERC5 function. 
The VLPs produced in the viral supernatant signaled that Env interferes with a HERC5-
mediated antiviral process. The VLPs measure the amount of Gag protein particles being 
released at the cell membrane. This could indicate that the mechanism being antagonized 
is the process of attaching an ISG15 group to a Gag protein, a mechanism conducted by 
the HECT domain in HERC5. The qPCR assay displayed a rescue of GagRNA in the 
cellular extract; indicating the antagonism of the RLD domain of HERC5 as the RLD 
domain is required for the inhibition of the export of HIV-1 Gag mRNA. 
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The antagonism of restriction factor proteins by viral proteins can occur through a 
direct or indirect interaction between the two proteins. For example, in the antagonism of 
Tetherin by HIV-1 Vpu, co-immunoprecipitation studies show Vpu interacts with 
Tetherin and decreases the level of Tetherin at the cell surface (Van Damme et al. 2008). 
Although this study was able to show the existence of an antagonistic function, future 
studies are needed to examine the possibility of an interaction. At this time whether 
HERC5 interacts with the gp120 or gp41 domain is unclear. Future studies will also 
examine if there is a direct or indirect interaction of HIV-1 Env and HERC5. 
Some questions that remain unanswered are that if the Env protein is interacting 
with the HERC5 RLD domain and suppressing its function, or blocking the enzymatic 
activity of the HECT domain (ISGylation), is it possible that both antiviral functions of 
HERC5 are being antagonized by Env? Furthermore, could Env be causing HERC5 to be 
degraded intracellularly and thus allowing HIV replication to proceed?  
The interaction studies (co-IP) failed to provide sufficient insight into the 
potential interaction occurring between the HERC5 and the HIV-1 Env protein. However, 
the experiments conducted were not definitive as our input was not present in the assays. 
Future protein-protein interaction assays are needed to determine if HIV-1 Env and 
HERC5 interact and if contributes to the antagonism by interacting with HERC5 and 
prevent it from carrying out its antiviral functions. For example, the interaction between 
IIIB and HERC5 could block the enzymatic site of HERC5. Even if a direct interaction 
does not occur, the possibility of an indirect interaction between the two proteins is still 
possible. To assess if HERC5 co-localizes with Env, I cloned HERC5 and Env into two 
individual Venus protein vectors. These vectors will allow us to conduct a Bimolecular 
fluorescence complementation (BiFC) assay which will allow us to visualize any co-
localization that occurs between HIV-1 Env and HERC5, utilizing fluorescence 
microscopy (Kerppola 2008). The presence of the Env protein is signalled by a red 
fluorescence while the presence of HERC5 is signalled by green fluorescence. If the two 
proteins of interest interact, it will cause the Venus proteins present in the two vectors to 
interact as well, producing a yellow pigment.  
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The revelation of a HERC5 antagonist led us to ask questions about how Env is 
causing this antagonism; particularly which amino acid residue(s) were causing an 
antagonistic effect. While functionally conserved, the two envelope proteins, IIIB and 
BaL, differ in their sequence and thus their expressed amino acids. Although both 
proteins are HIV-1 Env proteins, it is interesting that they do not share secondary 
functionality (HERC5 antagonism). However, the lack of shared functionality is not 
surprising given the differences observed between the amino acid sequences of the two 
proteins. Sequence diversity between the two variants of HIV-1 Envelope used in this 
experiment gives rise to different tropism (IIIB is R5 tropic and X4 tropic) but it is 
unclear whether tropism is a factor in antagonism.  
Further analysis of the sequences revealed many amino acid differences between 
the two Env proteins. The mutation of 4 particular amino acid residues (A723T, S724P, 
R725G, and G730E) in the cytoplasmic tail in gp41 of Env BaL (BaL mut) revealed that 
these particular amino acids were not responsible for the antagonistic activity. It is 
however possible that other residues which are different in the two proteins could be the 
cause for the observed antagonism by IIIB (Figure 12, 13). Further investigation needs to 
be conducted to pinpoint more amino acid residues that are divergent between the two 
Env proteins. The plasmids generated from swapping the gp41/gp120 domains between 
the two HIV-1 Env proteins will hopefully shed more light on the region responsible 
(Figure 19).  
Although additional replicates are needed, my preliminary screen of several 
different patient-derived HIV-1 Env proteins identified one patient of interest, in which 
Env was able to antagonize the function of HERC5 (patient #11187) by rescuing HIV-1 
Gag protein production. The sequence of HIV-1 proteins can greatly influence the 
phenotype and progression of the virus. Patients containing viruses with varying Vpu 
sequences, showed a variance in viral replication in the presence of IFN, alongside 
differences in the efficiency of viral budding from cells expressing BST2/Tetherin was 
observed (Vanwalscappel et al. 2017). Moreover, a study showed that there is a 
correlation between HIV-1 envelope sequences and slower disease progression in 
infected individuals (Venner et al. 2016).  
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 I showed that HIV-1 Env (IIIB) is a potential antagonist for the IFN induced 
restriction factor, HERC5. However, we were unable to identify the particular mechanism 
of antagonism which was occurring and whether it was caused by a direct or indirect 
interaction. To identify the key amino acid determinants of antagonism, I generated a 
swap mutation where I exchanged the gp120 domains of Env between the two different 
envelope proteins (IIIB and BaL). Future investigation will include testing these two new 
proteins in the same viral assay we used to test antagonistic proteins. However, assessing 
the biological implications of this experiment is imperative. In future studies, protein that 
display antagonistic capability will be cloned into the HIV-1 lab adapted vector 
containing the entire sequence of HIV-1. To assess if the effect of the antagonism is 
prevalent in infectious conditions, a TZM-bl assay can be conducted to understand the 
restriction conferred by HERC5 and the viral response after a single round of HIV-1 
infection (Sarzotti-Kelsoe et al. 2014).    
 My investigation into HERC5 antagonism revealed another potential protein of 
interest - HIV-1 Vpu. Vpu is an 81-amino acid protein whose primary function is to 
increase the release of progeny from infected host cells (Bour et al.1995). Interestingly, 
Vpu downregulates CD4 by binding to CD4 in the rough endoplasmic reticulum, thereby 
allowing CD4 to be ubiquitinated by E3 ligase proteins and targeted for degradation 
(Andrew & Strebel, 2010). It is worth examining the involvement of HERC5 in regard to 
Vpu activity. Preliminary data from my study showed that Vpu was able to rescue 
intracellular Gag RNA level and viral particle production thus possibly antagonizing 
HERC5 but additional investigation needs to be conducted to fully understand the 
interplay between Vpu and HERC5. 
Whether HERC5 interacts with Vpu is also a question for future studies. This can 
be analyzed by undertaking co-IP or BiFC assays as described above. How antagonism 
with Vpu evolves in vivo is another question that needs to be answered. Examining Vpu 
and HERC5 interactions using patient derived Vpu samples cloned into an HIV backbone 
would clarify antagonistic mechanisms and provide insight into this “unique” viral 
protein. This novel ability is consistent with recent studies showing Vpu is responsible 
for facilitating the degradation of the ISG15 E2 conjugating enzyme and thereby 
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decreasing cellular ISGylation (Jain et al. 2018). ISGylation is a HERC5 mediated 
process of attaching a ISG15 group to a substrate. In the case of HIV-1, conjugating an 
ISG15 group to the HIV-1 Gag protein prevents the budding of the replicated virions 
from the host cell membrane.  
Although the western blot and qPCR assessed the level of Gag (protein or RNA), 
this study should examine the presence and expression of HERC5 protein when it is co-
transfected with HIV-1 proteins. Similarly, the protein or RNA expression levels of HIV-
1 proteins (Env and Vpu) should be measured to ensure that they are in fact responsible 
for the antagonism of HERC5. Moreover, the effect of co-transfecting our empty vector 
with our HIV-1 Env and Vpu – without HERC5 – need to be studied to ensure the level 
of Gag protein is not different from the control conditions (Figure 12, 14).  
 In summary, I uncovered a unique function for potentially two different HIV-1 
proteins. HIV-1 Env IIIB and Vpu were able to rescue Gag RNA levels intracellularly as 
well as viral particle production from the antiviral inhibition of HERC5. These findings 
represent yet another way the virus is able to overcome host immunity. Restriction factors 
are vital in the defense of a zoonotic pathogen. Examining HERC5 antiviral activity and 
viral antagonism in simian HERC5 in conjunction with SIV, particularly whether the 
mechanisms of antagonism and viral restriction is conserved between closely related 
species, (i.e. non-human primates) would shed light on the dynamic co-evolution between 
viruses and hosts. Advances in restriction factor research will continue to provide us vital 
insights in cell biology and host immunity. 
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